|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet JM: Treatment of hepatocellular
carcinoma. Curr Treat Options Gastroenterol. 7:431–441. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bruix J, Reig M and Sherman M:
Evidence-based diagnosis, staging, and treatment of patients with
hepatocellular carcinoma. Gastroenterology. 150:835–853. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao F, Korangy F and Greten TF: Cellular
immune suppressor mechanisms in patients with hepatocellular
carcinoma. Dig Dis. 30:477–482. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harding JJ, El Dika I and Abou-Alfa GK:
Immunotherapy in hepatocellular carcinoma: Primed to make a
difference? Cancer. 122:367–377. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Steinman RM and Cohn ZA: Pillars Article:
Identification of a novel cell type in peripheral lymphoid organs
of mice. I. Morphology, quantitation, tissue distribution. J. Exp.
Med.1973. 137: 1142–1162. J Immunol. 178:5–25. 2007.PubMed/NCBI
|
|
7
|
Sun K, Wang L and Zhang Y: Dendritic cell
as therapeutic vaccines against tumors and its role in therapy for
hepatocellular carcinoma. Cell Mol Immunol. 3:197–203.
2006.PubMed/NCBI
|
|
8
|
Ge C, Xing Y, Wang Q, Xiao W, Lu Y, Hu X,
Gao Z, Xu M, Ma Y, Cao R, et al: Improved efficacy of therapeutic
vaccination with dendritic cells pulsed with tumor cell lysate
against hepatocellular carcinoma by introduction of 2 tandem
repeats of microbial HSP70 peptide epitope 407–426 and OK-432. Int
Immunopharmacol. 11:2200–2207. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee WC, Wang HC, Hung CF, Huang PF, Lia CR
and Chen MF: Vaccination of advanced hepatocellular carcinoma
patients with tumor lysate-pulsed dendritic cells: A clinical
trial. J Immunother. 28:496–504. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee JH, Lee Y, Lee M, Heo MK, Song JS, Kim
KH, Lee H, Yi NJ, Lee KW, Suh KS, et al: A phase I/IIa study of
adjuvant immunotherapy with tumour antigen-pulsed dendritic cells
in patients with hepatocellular carcinoma. Br J Cancer.
113:1666–1676. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun X, Zhang J, Wang L and Tian Z: Growth
inhibition of human hepatocellular carcinoma cells by blocking
STAT3 activation with decoy-ODN. Cancer Lett. 262:201–213. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sui Q, Zhang J, Sun X, Zhang C, Han Q and
Tian Z: NK cells are the crucial antitumor mediators when
STAT3-mediated immunosuppression is blocked in hepatocellular
carcinoma. J Immunol. 193:2016–2023. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Murone M, Chessex A Vaslin, Attinger A,
Ramachandra R, Shetty SJ, Daginakatte G, Sengupta S, Marappan S,
Dhodheri S, Rigotti S, et al: Debio 0617B inhibits growth of
STAT3-driven solid tumors through combined inhibition of JAK, SRC,
and class III/V receptor tyrosine kinases. Mol Cancer Ther.
15:2334–2343. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hillmer EJ, Zhang H, Li HS and Watowich
SS: STAT3 signaling in immunity. Cytokine Growth Factor Rev.
31:1–15. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu H, Kortylewski M and Pardoll D:
Crosstalk between cancer and immune cells: Role of STAT3 in the
tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nelson EA, Walker SR, Kepich A, Gashin LB,
Hideshima T, Ikeda H, Chauhan D, Anderson KC and Frank DA:
Nifuroxazide inhibits survival of multiple myeloma cells by
directly inhibiting STAT3. Blood. 112:5095–5102. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang F, Hu M, Lei Q, Xia Y, Zhu Y, Song X,
Li Y, Jie H, Liu C, Xiong Y, et al: Nifuroxazide induces apoptosis
and impairs pulmonary metastasis in breast cancer model. Cell Death
Dis. 6:e17012015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang WT, Chen HM, Yin SY, Chen YH, Wen
CC, Wei WC, Lai P, Wang CH and Yang NS: Specific Dioscorea
phytoextracts enhance potency of TCL-loaded DC-based cancer
vaccines. Evid Based Complement Alternat Med. 2013:9320402013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yin SY, Wang CY and Yang NS: Interleukin-4
enhances trafficking and functional activities of GM-CSF-stimulated
mouse myeloid-derived dendritic cells at late differentiation
stage. Exp Cell Res. 317:2210–2221. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nefedova Y, Cheng P, Gilkes D, Blaskovich
M, Beg AA, Sebti SM and Gabrilovich DI: Activation of dendritic
cells via inhibition of Jak2/STAT3 signaling. J Immunol.
175:4338–4346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang JD, Nakamura I and Roberts LR: The
tumor microenvironment in hepatocellular carcinoma: Current status
and therapeutic targets. Semin Cancer Biol. 21:35–43. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kalinski P: Dendritic cells in
immunotherapy of established cancer: Roles of signals 1, 2, 3 and
4. Curr Opin Investig Drugs. 10:526–535. 2009.PubMed/NCBI
|
|
23
|
Wang T, Niu G, Kortylewski M, Burdelya L,
Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola
D, et al: Regulation of the innate and adaptive immune responses by
Stat-3 signaling in tumor cells. Nat Med. 10:48–54. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cacalano NA: Regulation of natural killer
cell function by STAT3. Front Immunol. 7:1282016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hollander L, Guo X, Velazquez H, Chang J,
Safirstein R, Kluger H, Cha C and Desir GV: Renalase expression by
melanoma and tumor-associated macrophages promotes tumor growth
through a STAT3-mediated mechanism. Cancer Res. 76:3884–3894. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yue C, Shen S, Deng J, Priceman SJ, Li W,
Huang A and Yu H: STAT3 in CD8+ T cells inhibits their
tumor accumulation by downregulating CXCR3/CXCL10 axis. Cancer
Immunol Res. 3:864–870. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ghoshal S, Fuchs BC and Tanabe KK: STAT3
is a key transcriptional regulator of cancer stem cell marker CD133
in HCC. Hepatobiliary Surg Nutr. 5:201–203. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zheng X, Xu M, Yao B, Wang C, Jia Y and
Liu Q: IL-6/STAT3 axis initiated CAFs via up-regulating TIMP-1
which was attenuated by acetylation of STAT3 induced by PCAF in HCC
microenvironment. Cell Signal. 28:1314–1324. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang Q, Jiang J and Liu J: CCR5 blockade
suppresses melanoma development through inhibition of IL-6-Stat3
pathway via upregulation of SOCS3. Inflammation. 38:2049–2056.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Delirezh N, Moazzeni SM, Shokri F,
Shokrgozar MA, Atri M and Kokhaei P: Autologous dendritic cells
loaded with apoptotic tumor cells induce T cell-mediated immune
responses against breast cancer in vitro. Cell Immunol. 257:23–31.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang DH, Park JS, Jin CJ, Kang HK, Nam JH,
Rhee JH, Kim YK, Chung SY, Choi SJ, Kim HJ, et al: The dysfunction
and abnormal signaling pathway of dendritic cells loaded by tumor
antigen can be overcome by neutralizing VEGF in multiple myeloma.
Leuk Res. 33:665–670. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jia H, Li Y, Zhao T, Li X, Hu J, Yin D,
Guo B, Kopecko DJ, Zhao X, Zhang L, et al: Antitumor effects of
Stat3-siRNA and endostatin combined therapies, delivered by
attenuated Salmonella, on orthotopically implanted hepatocarcinoma.
Cancer Immunol Immunother. 61:1977–1987. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
McMichael EL, Jaime-Ramirez AC,
Guenterberg KD, Luedke E, Atwal LS, Campbell AR, Hu Z, Tatum AS,
Kondadasula SV, Mo X, et al: IL-21 enhances natural killer cell
response to cetuximab-coated pancreatic tumor cells. Clin Cancer
Res. 23:489–502. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Iraolagoitia XL, Spallanzani RG, Torres
NI, Araya RE, Ziblat A, Domaica CI, Sierra JM, Nuñez SY, Secchiari
F, Gajewski TF, et al: NK cells restrain spontaneous antitumor
CD8+ T cell priming through PD-1/PD-L1 interactions with
dendritic cells. J Immunol. 197:953–961. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kozlowska AK, Tseng HC, Kaur K, Topchyan
P, Inagaki A, Bui VT, Kasahara N, Cacalano N and Jewett A:
Resistance to cytotoxicity and sustained release of interleukin-6
and interleukin-8 in the presence of decreased interferon-γ after
differentiation of glioblastoma by human natural killer cells.
Cancer Immunol Immunother. 65:1085–1097. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xia Y, Song X, Li D, Ye T, Xu Y, Lin H,
Meng N, Li G, Deng S, Zhang S, et al: YLT192, a novel, orally
active bioavailable inhibitor of VEGFR2 signaling with potent
antiangiogenic activity and antitumor efficacy in preclinical
models. Sci Rep. 4:60312014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ferrara N: VEGF and the quest for tumour
angiogenesis factors. Nat Rev Cancer. 2:795–803. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dong W, Xian Y, Yuan W, Huifeng Z, Tao W,
Zhiqiang L, Shan F, Ya F, Hongli W, Jinghuan W, et al: Catalpol
stimulates VEGF production via the JAK2/STAT3 pathway to improve
angiogenesis in rats' stroke model. J Ethnopharmacol. 191:169–179.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Alvarez JV, Febbo PG, Ramaswamy S, Loda M,
Richardson A and Frank DA: Identification of a genetic signature of
activated signal transducer and activator of transcription 3 in
human tumors. Cancer Res. 65:5054–5062. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hsieh FC, Cheng G and Lin J: Evaluation of
potential Stat3-regulated genes in human breast cancer. Biochem
Biophys Res Commun. 335:292–299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Miklossy G, Hilliard TS and Turkson J:
Therapeutic modulators of STAT signalling for human diseases. Nat
Rev Drug Discov. 12:611–629. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Walker SR, Xiang M and Frank DA: Distinct
roles of STAT3 and STAT5 in the pathogenesis and targeted therapy
of breast cancer. Mol Cell Endocrinol. 382:616–621. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cheung TH, Chung TK, Lo KW, Yu MY,
Krajewski S, Reed JC and Wong YF: Apotosis-related proteins in
cervical intraepithelial neoplasia and squamous cell carcinoma of
the cervix. Gynecol Oncol. 86:14–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hunter AM, LaCasse EC and Korneluk RG: The
inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis.
12:1543–1568. 2007. View Article : Google Scholar : PubMed/NCBI
|
